Development of a Sustained Release Oral Formulation of sGC 1061, A New Therapeutic Agent for the Treatment of Alzheimer's Disease Related Cognitive Deficiency

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
Principal Investigator Last Name
Awardee Organization
Awardee State
Contact PI Country
Project Detail
Funding Opportunity Announcement
FY Overall Cost
Funding Organization
Agency/Funding Organization
Funding Organization Country